Answers are grounded in this paper and cite their sources.
Graphical AbstractRelationships of BNP to Mortality in Adult Congenital Heart Disease (L) and in Chronic Non-Congenital Heart Failure (R)Across 9 categories of Adult Congenital Heart Disease (ACHD) mortality varied over a 10-fold range.Baseline median BNP values over the 9 diagnoses were confined between 28 and 62ng/L.No clear graded increase in BNP with rising mortality.(Yumita Y, Xu Z, Diller G-P, Kempny A, Rafiq I, Montanaro C et al. Baseline and Serial BNP Measurements Predict Long-Term Mortality in Adults with Congenital Heart Disease: A study including 3,392 patients. Eur Heart J 2024.)In non-congenital adult HF with reduced LVEF mortality varied over 4-5 fold range.Baseline BNP extended over a more than 20 fold range between <16 to >442ng/L.Clear graded increase in BNP with rising mortality.(Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006 ;52:1528-38.)The relationships between BNP and mortality in chronic Adult CHD (i) differ markedly from that seen in chronic non-congenital HF and (ii) differ between ACHD diagnoses.
No takes yet. Share an insight, caveat, or question.
Mark Richards (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: